JP2021524267A5 - - Google Patents

Info

Publication number
JP2021524267A5
JP2021524267A5 JP2021500295A JP2021500295A JP2021524267A5 JP 2021524267 A5 JP2021524267 A5 JP 2021524267A5 JP 2021500295 A JP2021500295 A JP 2021500295A JP 2021500295 A JP2021500295 A JP 2021500295A JP 2021524267 A5 JP2021524267 A5 JP 2021524267A5
Authority
JP
Japan
Prior art keywords
sequence
antibody molecule
domain
ids
molecule according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021500295A
Other languages
English (en)
Japanese (ja)
Other versions
JP7397055B2 (ja
JP2021524267A (ja
Filing date
Publication date
Priority claimed from GBGB1811407.4A external-priority patent/GB201811407D0/en
Priority claimed from GBGB1818281.6A external-priority patent/GB201818281D0/en
Priority claimed from GBGB1902598.0A external-priority patent/GB201902598D0/en
Application filed filed Critical
Priority claimed from PCT/EP2019/068796 external-priority patent/WO2020011966A1/en
Publication of JP2021524267A publication Critical patent/JP2021524267A/ja
Publication of JP2021524267A5 publication Critical patent/JP2021524267A5/ja
Priority to JP2023202717A priority Critical patent/JP7701964B2/ja
Application granted granted Critical
Publication of JP7397055B2 publication Critical patent/JP7397055B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021500295A 2018-07-12 2019-07-12 Cd137及びox40に結合する抗体分子 Active JP7397055B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023202717A JP7701964B2 (ja) 2018-07-12 2023-11-30 Cd137及びox40に結合する抗体分子

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1811407.4A GB201811407D0 (en) 2018-07-12 2018-07-12 Antibody molecules that bind CD137 and OX40
GB1811407.4 2018-07-12
GB1818281.6 2018-11-09
GBGB1818281.6A GB201818281D0 (en) 2018-11-09 2018-11-09 Antibody molecules that bind CD137 and OX40
GB1902598.0 2019-02-26
GBGB1902598.0A GB201902598D0 (en) 2019-02-26 2019-02-26 Antibody molecules that bind cd137 and ox40
PCT/EP2019/068796 WO2020011966A1 (en) 2018-07-12 2019-07-12 Antibody molecules that bind cd137 and ox40

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023202717A Division JP7701964B2 (ja) 2018-07-12 2023-11-30 Cd137及びox40に結合する抗体分子

Publications (3)

Publication Number Publication Date
JP2021524267A JP2021524267A (ja) 2021-09-13
JP2021524267A5 true JP2021524267A5 (cg-RX-API-DMAC7.html) 2022-07-20
JP7397055B2 JP7397055B2 (ja) 2023-12-12

Family

ID=67383740

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021500295A Active JP7397055B2 (ja) 2018-07-12 2019-07-12 Cd137及びox40に結合する抗体分子
JP2023202717A Active JP7701964B2 (ja) 2018-07-12 2023-11-30 Cd137及びox40に結合する抗体分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023202717A Active JP7701964B2 (ja) 2018-07-12 2023-11-30 Cd137及びox40に結合する抗体分子

Country Status (15)

Country Link
US (1) US12252537B2 (cg-RX-API-DMAC7.html)
EP (1) EP3820898B1 (cg-RX-API-DMAC7.html)
JP (2) JP7397055B2 (cg-RX-API-DMAC7.html)
KR (1) KR102987897B1 (cg-RX-API-DMAC7.html)
CN (1) CN112424229B (cg-RX-API-DMAC7.html)
AU (1) AU2019301206B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000282A2 (cg-RX-API-DMAC7.html)
CA (1) CA3106048A1 (cg-RX-API-DMAC7.html)
ES (1) ES3044118T3 (cg-RX-API-DMAC7.html)
IL (1) IL280002B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021000399A (cg-RX-API-DMAC7.html)
SG (1) SG11202100172XA (cg-RX-API-DMAC7.html)
TW (1) TWI847989B (cg-RX-API-DMAC7.html)
WO (1) WO2020011966A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100718B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CA3086098A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Fc binding fragments comprising a pd-l1 antigen-binding site
CN119735681A (zh) 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
BR112021000394A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a pd-l1 e cd137
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
KR20230167025A (ko) * 2021-02-17 2023-12-07 압테보 리서치 앤드 디벨롭먼트 엘엘씨 4-1bb 및 ox40 결합 단백질을 포함하는 조성물 및 이의 용도
IL307744A (en) * 2021-04-22 2023-12-01 Astellas Pharma Inc Anti-CLDN4/anti-CD137 bispecific antibody
CN114478771B (zh) * 2021-12-14 2024-06-25 英诺湖医药(杭州)有限公司 Ox40抗体及其医药用途
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
EP4600651A1 (en) * 2024-02-06 2025-08-13 Consiglio Nazionale Delle Ricerche - CNR Method for diagnosing coeliac disease
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
EP4686882A1 (en) 2024-07-31 2026-02-04 BDR Thermea Group B.V. System to prevent frost damage to an outdoor heating appliance

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2245404C3 (de) 1972-09-15 1978-08-31 Robert Bosch Gmbh, 7000 Stuttgart Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben
JPS531908B2 (cg-RX-API-DMAC7.html) 1973-11-12 1978-01-23
JPS5746634B2 (cg-RX-API-DMAC7.html) 1974-05-10 1982-10-04
JPS5146628A (ja) 1974-10-17 1976-04-21 Nippon Denso Co Teikoirisupaakupuragu
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE69833459T2 (de) 1997-12-01 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung
DE19818214A1 (de) 1998-04-24 1999-10-28 Bosch Gmbh Robert Zündkerze für eine Brennkraftmaschine
MXPA01011950A (es) 1999-05-27 2002-05-06 Gov Health & Human Serv Inmunoconjugados que tienen alta afinidad de enlace.
JP4578025B2 (ja) 2001-07-06 2010-11-10 日本特殊陶業株式会社 スパークプラグ
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
WO2006088447A1 (en) 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
EP2322560B1 (en) 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
PL3241842T3 (pl) 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
KR101559599B1 (ko) 2007-11-26 2015-10-12 바이엘 인텔렉쳐 프로퍼티 게엠베하 항-메소텔린 항체 및 이의 용도
SI2242771T1 (sl) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AU2009313877A1 (en) 2008-11-13 2011-06-30 Emergent Product Development Seattle, Llc CD37 immunotherapeutic combination therapies and uses thereof
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CA2756393C (en) 2009-03-24 2017-06-20 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
AU2011349443B2 (en) 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
JP5276742B1 (ja) 2012-08-09 2013-08-28 日本特殊陶業株式会社 点火プラグ
US9416190B2 (en) 2012-09-27 2016-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
RS60538B1 (sr) 2013-03-15 2020-08-31 Glaxosmithkline Ip Dev Ltd Anti-lag-3 vezujući proteini
WO2014151910A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
WO2015198312A1 (en) 2014-06-24 2015-12-30 Ccam Therapeutics Ltd. Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
JP5902757B2 (ja) 2014-06-24 2016-04-13 日本特殊陶業株式会社 スパークプラグ
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
KR20170041249A (ko) 2014-08-10 2017-04-14 페더럴-모굴 이그니션 컴퍼니 개선된 시일을 가진 점화 플러그
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗-ox40抗體及其用途
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
TW201632559A (zh) 2015-02-22 2016-09-16 索倫多醫療公司 結合cd137之抗體治療劑
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
BR112017024770A2 (pt) 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
JP6025921B1 (ja) 2015-06-22 2016-11-16 日本特殊陶業株式会社 スパークプラグ
MX2018000447A (es) 2015-07-15 2018-08-15 Pieris Pharmaceuticals Gmbh Novedosas proteinas especificas para lag-3.
CN114853891A (zh) 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
BR112018000366A2 (pt) 2015-08-07 2018-09-11 Pieris Pharmaceuticals Gmbh polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão
US10875926B2 (en) 2015-09-22 2020-12-29 Dingfu Biotarget Co., Ltd. Fully human antibody against human CD 137
KR101782487B1 (ko) 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 신규 항-메소텔린 항체 및 이를 포함하는 조성물
MY206406A (en) 2015-10-02 2024-12-16 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
GB201519481D0 (en) * 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
US20190330336A1 (en) 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
IL304871A (en) 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
CN108602371B (zh) 2016-03-18 2020-03-24 大日本印刷株式会社 中间转印介质、中间转印介质与热转印片的组合、以及印刷物的形成方法
BR112018071612A2 (pt) 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
IL321475A (en) 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
KR20190014525A (ko) 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
US20190106494A1 (en) 2016-06-13 2019-04-11 Askgene Pharma Inc. PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
CN107523546A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的nk细胞及其用途
JP7085709B2 (ja) 2016-06-20 2022-06-17 エフ-スター セラピューティクス リミテッド Pd-l1及びlag-3に結合する結合分子
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
EP3515951B1 (en) 2016-09-23 2024-02-28 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
GB201616699D0 (en) 2016-09-30 2016-11-16 Mab Designs Ltd Antibodies
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
WO2018115859A1 (en) 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
US11260117B2 (en) 2017-05-26 2022-03-01 Novimmune Sa Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
JP2020522495A (ja) 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
CA3086098A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Fc binding fragments comprising a pd-l1 antigen-binding site
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
BR112021000394A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a pd-l1 e cd137
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
KR20220008316A (ko) 2019-05-14 2022-01-20 에프-스타 테라퓨틱스 리미티드 Lag-3/pd-l1 이중특이적 항체의 투여를 위한 투여 요법

Similar Documents

Publication Publication Date Title
JP2021524268A5 (cg-RX-API-DMAC7.html)
JP2023178323A5 (cg-RX-API-DMAC7.html)
JP2021525546A5 (cg-RX-API-DMAC7.html)
JP2021524269A5 (cg-RX-API-DMAC7.html)
JP2021524278A5 (cg-RX-API-DMAC7.html)
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
TWI769537B (zh) 標靶bcma的抗體、雙專一性抗體及其用途
JP2022061992A5 (cg-RX-API-DMAC7.html)
JP2021508469A5 (cg-RX-API-DMAC7.html)
FI3820894T3 (fi) Mesoteliinia ja vastaavasti cd137:ää sitovia molekyylejä
JP2019533719A5 (cg-RX-API-DMAC7.html)
JP2018108081A5 (cg-RX-API-DMAC7.html)
JP2020532965A5 (cg-RX-API-DMAC7.html)
JP2021511058A5 (cg-RX-API-DMAC7.html)
IL312961A (en) Anti-tmprss2 antibodies and antigen-binding fragments
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
JP2021524275A5 (cg-RX-API-DMAC7.html)
JP2021510521A5 (cg-RX-API-DMAC7.html)
JP2018527887A5 (cg-RX-API-DMAC7.html)
IL292780A (en) A new 4-1bbl trimer containing antigen-binding molecules
JP2019526273A5 (cg-RX-API-DMAC7.html)
JP2021524478A5 (cg-RX-API-DMAC7.html)
AR122761A1 (es) Moléculas de unión a antígeno biespecíficas anti-cd3 / anti-cd28
HRP20110187T1 (hr) Multispecifične deimunizirane tvari koje vežu cd3
RU2012118636A (ru) Молекула, специфически связывающаяся с rsv